Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4467 |
Name | clear cell renal cell carcinoma |
Definition | A renal cell carcinoma that has_material_basis_in cells that appear very pale or clear when examined under microscope. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer renal carcinoma renal cell carcinoma clear cell renal cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
VHL over exp | Cediranib + Saracatinib | clear cell renal cell carcinoma | no benefit | detail... |
VHL inact mut | PT2399 | clear cell renal cell carcinoma | conflicting | detail... |
TP53 R248W VHL inact mut | PT2399 | clear cell renal cell carcinoma | resistant | detail... |
PBRM1 mutant | Everolimus | clear cell renal cell carcinoma | conflicting | detail... |
PBRM1 inact mut | Nivolumab | clear cell renal cell carcinoma | sensitive | detail... |
PBRM1 inact mut | Ipilimumab + Nivolumab | clear cell renal cell carcinoma | sensitive | detail... |
PBRM1 inact mut | Atezolizumab | clear cell renal cell carcinoma | sensitive | detail... |
PBRM1 Y331* | Nivolumab | clear cell renal cell carcinoma | predicted - sensitive | detail... |
PBRM1 A249fs | Nivolumab | clear cell renal cell carcinoma | no benefit | detail... |
PBRM1 E291* | Nivolumab | clear cell renal cell carcinoma | no benefit | detail... |
PBRM1 G2fs | Nivolumab | clear cell renal cell carcinoma | no benefit | detail... |
PBRM1 K135fs | Nivolumab | clear cell renal cell carcinoma | predicted - sensitive | detail... |
PBRM1 K154fs | Nivolumab | clear cell renal cell carcinoma | predicted - sensitive | detail... |
PBRM1 K619fs | Ipilimumab + Nivolumab | clear cell renal cell carcinoma | predicted - sensitive | detail... |
PBRM1 K621* | Nivolumab | clear cell renal cell carcinoma | no benefit | detail... |
PBRM1 N463fs | Nivolumab | clear cell renal cell carcinoma | predicted - sensitive | detail... |
PBRM1 N609fs | Nivolumab | clear cell renal cell carcinoma | no benefit | detail... |
PBRM1 R941fs | Nivolumab | clear cell renal cell carcinoma | no benefit | detail... |
PBRM1 S681R | Nivolumab | clear cell renal cell carcinoma | predicted - sensitive | detail... |
PBRM1 W141_L145delinsC | Nivolumab | clear cell renal cell carcinoma | no benefit | detail... |
PBRM1 Y106* | Ipilimumab + Nivolumab | clear cell renal cell carcinoma | predicted - sensitive | detail... |
PBRM1 Y608fs | Nivolumab | clear cell renal cell carcinoma | no benefit | detail... |
PBRM1 mutant | Nivolumab | clear cell renal cell carcinoma | predicted - sensitive | detail... |
TSC2 inact mut | N/A | clear cell renal cell carcinoma | not applicable | detail... |
TSC1 inact mut | N/A | clear cell renal cell carcinoma | not applicable | detail... |
VHL inact mut | N/A | clear cell renal cell carcinoma | not applicable | detail... |
PTEN loss | Everolimus | clear cell renal cell carcinoma | sensitive | detail... |
PTEN loss | Temsirolimus | clear cell renal cell carcinoma | sensitive | detail... |
PBRM1 inact mut | PRT1419 | clear cell renal cell carcinoma | sensitive | detail... |
PBRM1 inact mut | PRT1419 + Sunitinib | clear cell renal cell carcinoma | sensitive | detail... |
PBRM1 inact mut | Everolimus + PRT1419 | clear cell renal cell carcinoma | sensitive | detail... |
PBRM1 inact mut | Cabozantinib + PRT1419 | clear cell renal cell carcinoma | sensitive | detail... |
PBRM1 inact mut | Pazopanib + PRT1419 | clear cell renal cell carcinoma | sensitive | detail... |
PBRM1 inact mut VHL loss | Belzutifan + PRT1419 | clear cell renal cell carcinoma | sensitive | detail... |
PBRM1 inact mut | PRT2527 | clear cell renal cell carcinoma | predicted - sensitive | detail... |
VHL N78K | Belzutifan | clear cell renal cell carcinoma | predicted - sensitive | detail... |
VHL T133fs | Belzutifan | clear cell renal cell carcinoma | predicted - sensitive | detail... |
EML4 - ALK | Crizotinib | clear cell renal cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00747305 | Phase I | Sunitinib | Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery | Terminated | USA | 0 |
NCT00831480 | Phase II | Everolimus | Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal | Terminated | USA | 0 |
NCT01038778 | Phase Ib/II | Entinostat Aldesleukin | Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01099423 | Phase III | Sunitinib | Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer | Unknown status | NLD | ITA | GBR | CAN | BEL | 0 |
NCT01158521 | Phase II | Pazopanib | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | Completed | USA | 0 |
NCT01392183 | Phase II | Diphenhydramine Temsirolimus Pazopanib | Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
NCT01499121 | Phase II | Sunitinib | Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule | Completed | CAN | 0 |
NCT01582204 | Phase I | Pazopanib Sunitinib | Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT01599754 | Phase III | Axitinib | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients | Terminated | USA | FRA | ESP | 6 |
NCT01599832 | Phase I | Pazopanib | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer | Terminated | USA | 0 |
NCT01684397 | Phase Ib/II | Bevacizumab + Pazopanib | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01835158 | Phase II | Cabozantinib Cabozantinib + Sunitinib | Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | Completed | USA | 0 |
NCT01999972 | Phase I | Axitinib + Crizotinib | A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT02060370 | Phase II | Sunitinib | Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | Completed | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02210117 | Phase II | Nivolumab Bevacizumab + Nivolumab Ipilimumab + Nivolumab | Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) | Active, not recruiting | USA | 0 |
NCT02293980 | Phase I | PT2385 Nivolumab + PT2385 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02307474 | Phase I | Pazopanib | A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | Withdrawn | USA | 0 |
NCT02315066 | Phase I | PF-04518600 PF-04518600 + Utomilumab | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | Completed | USA | NLD | FRA | 1 |
NCT02348008 | Phase Ib/II | Bevacizumab + Pembrolizumab | Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma | Completed | USA | 0 |
NCT02386111 | Phase Ib/II | Sunitinib + Varlilumab | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | Terminated | USA | 0 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Completed | USA | POL | ESP | DEU | CHE | BEL | AUT | AUS | 1 |
NCT02535533 | Phase I | Axitinib + Selenomethionine | SLM + Axitinib for Clear Cell RCC | Active, not recruiting | USA | 0 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02575222 | Phase I | Nivolumab | Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma | Completed | USA | 0 |
NCT02579811 | Phase II | Axitinib | Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer | Completed | USA | 0 |
NCT02595918 | Phase I | Nivolumab | Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer | Terminated | USA | 0 |
NCT02599324 | Phase Ib/II | Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib | A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | Completed | USA | GBR | ESP | 1 |
NCT02607553 | Phase II | Mipsagargin | Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA | Completed | USA | 0 |
NCT02626130 | Phase I | Tremelimumab | Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02667886 | Phase Ib/II | Axitinib X4P-001 | Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma | Completed | USA | 1 |
NCT02837991 | Phase Ib/II | CDX-014 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma | Terminated | USA | 0 |
NCT02853344 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) | Completed | 0 | |
NCT02885649 | Phase 0 | Enzalutamide | Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | Terminated | USA | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CHE | CAN | AUT | 3 |
NCT02974738 | Phase I | Belzutifan | A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors | Active, not recruiting | 0 | |
NCT02978404 | Phase II | Nivolumab | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | Completed | CAN | 0 |
NCT02989714 | Phase Ib/II | Aldesleukin + Nivolumab | Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer | Completed | USA | 0 |
NCT03015740 | Phase Ib/II | Nivolumab + Sitravatinib | MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC) | Completed | USA | 0 |
NCT03024996 | Phase III | Atezolizumab | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) | Terminated | USA | TUR | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT03035630 | Phase II | Avelumab Sunitinib | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | Withdrawn | USA | 0 |
NCT03108066 | Phase II | PT2385 | PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma | Completed | USA | 0 |
NCT03138512 | Phase III | Ipilimumab + Nivolumab | A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914) | Completed | USA | TUR | ROU | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT03141177 | Phase III | Cabozantinib + Ipilimumab + Nivolumab Sunitinib Cabozantinib + Nivolumab | A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) | Active, not recruiting | USA | TUR | ROU | POL | ITA | ISR | GRC | GBR | ESP | DEU | CZE | BRA | AUS | ARG | 4 |
NCT03149159 | Phase II | Ipilimumab + Nivolumab | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | Withdrawn | USA | 0 |
NCT03170960 | Phase Ib/II | Atezolizumab + Cabozantinib | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 0 |
NCT03173560 | Phase II | Everolimus + Lenvatinib | Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma | Completed | USA | ROU | POL | NLD | ITA | GRC | GBR | FIN | ESP | CZE | CAN | AUS | 4 |
NCT03200717 | Phase II | Pazopanib | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment | Completed | USA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUT | ARG | 1 |
NCT03260504 | Phase I | Aldesleukin + Pembrolizumab | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | Terminated | USA | 0 |
NCT03284385 | Phase II | Adavosertib | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | Active, not recruiting | USA | 0 |
NCT03294083 | Phase I | Cemiplimab + JX-594 | A Study of Recombinant Vaccinia Virus in Combination With REGN2810 for Renal Cell Carcinoma | Active, not recruiting | USA | AUS | 1 |
NCT03308396 | Phase Ib/II | Durvalumab + Guadecitabine Guadecitabine | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | Active, not recruiting | USA | 0 |
NCT03334409 | Phase II | Pazopanib | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT03341845 | Phase II | Avelumab + Axitinib | Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC | Recruiting | NLD | 0 |
NCT03354390 | Phase I | Autologous HERV-E TCR transduced T cells | HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03438708 | Phase II | Axitinib | Prior Axitinib as a Determinant of Outcome of Renal Surgery (PADRES) | Unknown status | USA | 0 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03680521 | Phase II | Nivolumab + Sitravatinib | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | Completed | USA | 0 |
NCT03682289 | Phase II | Ceralasertib + Olaparib Olaparib | Phase II Trial of AZD6738 Alone and in Combination With Olaparib | Recruiting | USA | 0 |
NCT03693612 | Phase Ib/II | GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab | GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT03741426 | Phase II | Durvalumab Cediranib Durvalumab + Olaparib Cediranib + Olaparib Olaparib | WIRE - Novel Treatments in Renal Cell Cancer (WIRE) | Recruiting | GBR | 0 |
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Terminated | USA | 0 |
NCT03829111 | Phase I | Ipilimumab + Nivolumab CBM588 + Ipilimumab + Nivolumab | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | Completed | USA | 0 |
NCT03875313 | Phase Ib/II | Talazoparib + Telaglenastat | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03937219 | Phase III | Cabozantinib + Nivolumab Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313) | Completed | USA | POL | NZL | NLD | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT04028245 | Phase I | Canakinumab + Spartalizumab | A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1) | Recruiting | USA | 0 |
NCT04071223 | Phase II | Cabozantinib + Radium Ra 223 dichloride Cabozantinib | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study | Recruiting | USA | 0 |
NCT04150562 | Phase II | Avelumab + rhIL-15 | Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma | Terminated | USA | 0 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Active, not recruiting | USA | SVK | AUS | 2 |
NCT04169711 | Phase I | ARO-HIF2 | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma | Completed | USA | 0 |
NCT04169841 | Phase II | Durvalumab + Olaparib + Tremelimumab | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) | Active, not recruiting | FRA | 0 |
NCT04195750 | Phase III | Belzutifan Everolimus | A Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | Active, not recruiting | USA | TUR | SWE | NOR | ITA | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | 8 |
NCT04276376 | Phase II | Atezolizumab + Rucaparib | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) | Suspended | FRA | 0 |
NCT04300140 | Phase Ib/II | AVB-S6-500 + Cabozantinib Cabozantinib | Efficacy and Safety Study of AVB-S6-500 in Patients With Clear Cell Renal Cell Carcinoma | Terminated | USA | 0 |
NCT04338269 | Phase III | Cabozantinib Atezolizumab + Cabozantinib | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03) | Active, not recruiting | USA | POL | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CAN | AUS | ARG | 3 |
NCT04374877 | Phase I | SRF388 | Study of SRF388 in Patients With Advanced Solid Tumors | Recruiting | USA | 2 |
NCT04388852 | Phase I | DS-3201b + Ipilimumab | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | Recruiting | USA | 0 |
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Completed | USA | FRA | ESP | CAN | 0 |
NCT04518046 | Phase I | Ipilimumab + Nivolumab + Sitravatinib | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | Completed | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04586231 | Phase III | Belzutifan + Lenvatinib Cabozantinib | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | Active, not recruiting | USA | ROU | POL | NLD | ITA | IRL | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
NCT04626479 | Phase Ib/II | Lenvatinib + MK-1308A Lenvatinib + MK-4280A Lenvatinib + Pembrolizumab Belzutifan + Lenvatinib + Pembrolizumab | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | Active, not recruiting | USA | POL | NZL | NLD | ISR | HUN | GBR | FRA | ESP | CAN | AUS | 3 |
NCT04626518 | Phase Ib/II | MK-4280A Lenvatinib + Pembrolizumab Belzutifan + Pembrolizumab MK-1308A MK-4830 + Pembrolizumab Belzutifan + Lenvatinib | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B) | Active, not recruiting | USA | POL | NZL | NLD | ISR | HUN | GBR | FRA | ESP | CAN | AUS | 2 |
NCT04627064 | Phase I | Abemaciclib + Belzutifan Abemaciclib | ABEMA Alone or in COMBO With MK-6482 | Active, not recruiting | USA | 0 |
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04777994 | Phase I | ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484 | A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | Recruiting | USA | ISR | FRA | ESP | 2 |
NCT04779151 | Phase II | Dostarlimab-gxly + Niraparib | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) | Suspended | FRA | 0 |
NCT04834778 | Phase I | HC-5404-FU | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | Completed | USA | 0 |
NCT04895748 | Phase I | DFF332 + Spartalizumab + Taminadenant DFF332 + Everolimus DFF332 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | Active, not recruiting | USA | ITA | FRA | ESP | CZE | 2 |
NCT04904302 | Phase II | Nivolumab + Sitravatinib | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | Active, not recruiting | USA | 0 |
NCT04991740 | Phase I | JNJ-78306358 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Completed | ISR | ESP | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05119335 | Phase Ib/II | NKT2152 | A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT05127824 | Phase II | Autologous alpha-DC1/TBVA vaccine + Cabozantinib | Autologous Dendritic Cell Vaccine in Kidney Cancer | Recruiting | USA | 0 |
NCT05148546 | Phase II | Ipilimumab + Nivolumab Nivolumab Nivolumab + Relatlimab | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO) | Recruiting | NLD | GBR | 0 |
NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT05277051 | Phase I | GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | AUS | 3 |
NCT05323045 | Phase I | BYON3521 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | Active, not recruiting | NLD | ITA | GBR | BEL | 0 |
NCT05363631 | Phase Ib/II | Axitinib + Pembrolizumab + Selenomethionine | Phase I/II Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | Recruiting | USA | 0 |
NCT05397093 | Phase I | ITIL-306 | ITIL-306 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05433142 | Phase I | XmAb819 | Study of XmAb819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT05501054 | Phase Ib/II | CPI-444 + Ipilimumab + Nivolumab | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | Recruiting | USA | 0 |
NCT05536141 | Phase I | AB521 | A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors (ARC-20) | Recruiting | USA | AUS | 1 |
NCT05544929 | Phase I | KFA115 KFA115 + Pembrolizumab | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Recruiting | USA | ITA | ESP | DEU | CAN | 4 |
NCT05578664 | Phase II | Pembrolizumab | Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer (PE-PE) | Recruiting | ITA | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05663710 | Phase II | 177Lu-girentuximab + Cabozantinib + Nivolumab | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | Active, not recruiting | USA | 0 |
NCT05665361 | Phase Ib/II | Palbociclib + PF-06801591 | Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) | Recruiting | USA | 0 |
NCT05672459 | Phase Ib/II | IVS-3001 Cyclophosphamide + Fludarabine | A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | Recruiting | USA | 0 |
NCT05703854 | Phase Ib/II | CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | Recruiting | USA | 0 |
NCT05769959 | Phase Ib/II | RO7515629 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Terminated | USA | 0 |
NCT05795595 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | Recruiting | USA | 0 |
NCT05805501 | Phase II | Axitinib + RO7247669 Axitinib + Pembrolizumab Axitinib + RO7247669 + Tiragolumab | A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | Active, not recruiting | USA | POL | GBR | FRA | ESP | DEU | AUS | 2 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05879822 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Active, not recruiting | TUR | ROU | NZL | HUN | GRC | BRA | 3 |
NCT05909995 | Phase I | INCB099280 + Ipilimumab | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | Active, not recruiting | USA | CAN | 1 |
NCT05935748 | Phase II | NKT2152 + Palbociclib + PF-06801591 NKT2152 + Palbociclib | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | Active, not recruiting | USA | 0 |
NCT05969496 | Phase II | Axitinib + Pembrolizumab | Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Associated Inferior Vena Cava Tumor Thrombus (NEOPAX) (NEOPAX) | Recruiting | USA | 0 |
NCT06052852 | Phase Ib/II | BDC-3042 + Pembrolizumab BDC-3042 | Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT06059014 | Phase Ib/II | 177Lu-rhPSMA-10.1 | Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer (PRadR) | Recruiting | FRA | 0 |
NCT06178614 | Phase I | JNJ-87890387 | A Study of JNJ-87890387 for Advanced Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT06191796 | Phase Ib/II | AB521 + Nivolumab + XL092 AB521 + XL092 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) | Active, not recruiting | USA | 0 |
NCT06240728 | Phase I | NPX887 | A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 | Recruiting | USA | 0 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06245915 | Phase Ib/II | AB-2100 | AB-2100, an Integrated Circuit T (ICT) Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) | Recruiting | USA | 0 |
NCT06307431 | Phase II | Pembrolizumab mRNA-4157 + Pembrolizumab | A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) | Recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | AUS | ARG | 3 |
NCT06318871 | Phase I | CIML-NK cells + Nogapendekin alfa inbakicept | A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Combination With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | Recruiting | USA | 0 |
NCT06380816 | Phase Ib/II | UCB4594 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Recruiting | GBR | 0 |
NCT06601296 | Phase II | IMSA101 + Nivolumab | Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (SPARK) | Not yet recruiting | USA | 0 |
NCT06660654 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Not yet recruiting | USA | 0 |